Search - tctmd.com

Displaying 41 - 60 of 64

Sort: Relevancy | Date

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

Todd Neale

August 26, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

Presentation EuroPCR 2018

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

Presenter: Panagiotis Xaplanteris

May 23, 2018

News Conference News EuroPCR 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

Caitlin E. Cox

May 22, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

Presentation CIT 2018

The study is presented on behalf of the FAME 2 Investigators

Presenter: William F. Fearon

March 23, 2018

News Conference News ACC 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

Caitlin E. Cox

March 10, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

L.A. McKeown

November 02, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

Presentation Stanford Coronary Physiology Conference 2017

Fifteen Minutes of FAME

Presenter: William F. Fearon

October 28, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

Caitlin E. Cox

March 14, 2017

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

Presentation Stanford Coronary Physiology Conference 2016

Will FFR-Directed PCI Be Better Than CABG? Update on the FAME 3 trial

Presenter: William F. Fearon

October 28, 2016

News Daily News

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

Michael O'Riordan

July 27, 2016

Advertisement

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

The study is presented on behalf of the FAME 2 Investigators

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Fifteen Minutes of FAME

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Will FFR-Directed PCI Be Better Than CABG? Update on the FAME 3 trial

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content